Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 11/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974901 | 0.93 | SLC2A1 (0.72) | SLC2A1POLBFLT3PDGFRBKIT | |
| SCHEMBL3980449 | 0.93 | SLC2A1 (0.78) | SLC2A1POLBFLT3PDGFRBKIT | |
| SCHEMBL6670648 | 0.90 | SLC2A1 (0.80) | SLC2A1POLBFLT3PDGFRBKIT | |
| SCHEMBL3976619 | 0.89 | SLC2A1 (0.64) | SLC2A1POLBFLT3PDGFRBKIT | |
| SCHEMBL3974647 | 0.87 | FLT3 (0.70) | SLC2A1POLBFLT3PDGFRBKIT | |
| SCHEMBL3980413 | 0.86 | SLC2A1 (0.62) | SLC2A1POLBFLT3MEN1KMT2A | |
| SCHEMBL3974464 | 0.83 | POLB (0.57) | SLC2A1POLBFLT3KMT2AMAPT | |
| SCHEMBL3973291 | 0.83 | SLC2A1 (0.64) | SLC2A1POLBFLT3PDGFRBKIT | |
| SCHEMBL6671471 | 0.83 | SLC2A1 (0.70) | SLC2A1POLBFLT3MEN1KMT2A | |
| SCHEMBL6668789 | 0.83 | POLB (0.62) | SLC2A1POLBFLT3PDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2004030672-A1 | USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | SLC2A1 1107/4885POLB 4723/4885FLT3 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.